NCT05188586 (NODMED) is a NA clinical trial of MRI/Imaging in Pancreatic Cancer, sponsored by ClearNote Health.

Who is sponsoring NCT05188586?

NCT05188586 is sponsored by ClearNote Health.

What drugs are being tested in NCT05188586?

Interventions in NCT05188586: MRI/Imaging.

What condition does NCT05188586 study?

NCT05188586 studies Pancreatic Cancer.

Is NCT05188586 still recruiting?

NCT05188586 is currently terminated. Last updated 19 September 2024.

Last reviewed 2024-09-19 · How we verify

NCT05188586: NODMED

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

New Onset Diabetes Management for Earlier Detection of Pancreatic Cancer (NODMED)

Terminated NA Last updated 19 September 2024

What this trial tests

NA trial testing MRI/Imaging in Pancreatic Cancer in 26 participants. Terminated before completion.

Timeline

31 October 2022

Primary endpoint
16 March 2023

16 March 2023

Quick facts

Lead sponsor	ClearNote Health
Phase	NA
Status	Terminated
Study type	INTERVENTIONAL
Allocation	non randomized
Design	sequential
Masking	none
Primary purpose	screening
Enrollment	26
Start date	31 October 2022
Primary completion	16 March 2023
Estimated completion	16 March 2023
Sites	5 locations across United States

Drugs / interventions tested

MRI/Imaging

Conditions studied

Pancreatic Cancer — all drugs for Pancreatic Cancer →

Sponsor

ClearNote Health — full company profile →

Who can join

50 and older, any sex, with Pancreatic Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Bluestar Genomics has developed a non-invasive test that aids in detection of occult pancreatic cancer in patients with new onset type II diabetes (NOD) who are 50 years old or older. The purpose of this study is to evaluate the performance of Bluestar Genomics early-detection pancreatic cancer test in a clinical setting. The study is prospective, longitudinal and interventional; tests will be ordered and results returned to site-investigators. If the test returns a pancreatic cancer signal "detected" result the study participant will undergo MRI imaging to evaluate for the presence of pancreatic cancer. The study is planned to enroll 6,550 newly diagnosed type 2 diabetic subjects according to inclusion and exclusion criteria.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Screening for pancreatic cancer has the potential to save lives, but is it practical?
Mazer BL, Lee JW, Roberts NJ, Chu LC, et al · · 2023 · cited 23× · PMID 37212770 · DOI 10.1080/17474124.2023.2217354
Liquid biopsies for cancer: From bench to clinic.
Chen Z, Li C, Zhou Y, Yao Y, et al · · 2023 · cited 12× · PMID 37492785 · DOI 10.1002/mco2.329

Verify or expand the search:

Other recruiting trials for Pancreatic Cancer

Currently open trials in the same condition.

NCT07126158 — Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma · Phase 2 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07439757 — AI-Powered Precision Decision-Making for Pancreatic Diseases · recruiting
NCT07409272 — A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherap · Phase 3 · recruiting
NCT07236177 — B-GLUCANCER2 : A Pilot Study Evaluating a New Method for Cancer Detection by Measuring the Activity of Different Glycosi · EARLY_PHASE1 · recruiting

Other ClearNote Health trials

Trials by the same sponsor.

NCT05188573 — EpiDetect Study: Clinical Validation of a Pancreatic Cancer Detection Test in New-Onset Diabetes Patients · NA · withdrawn
NCT03869814 — Non-invasive Liquid Biopsy Analysis of Epigenomics Signatures in Multiple Cancer Types · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05188586 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by ClearNote Health
Last refreshed: 19 September 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05188586.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing